MINDCURE is well-positioned to capitalize on its near-term revenue strategy, complete beta testing and launch of digital therapeutic tool iSTRYM and further its research into psychedelics VANCOUVER, BC, April 29, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( “MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy…


Previous articleBetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs
Next articleBexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation